Anti-B4-blocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models.

Shah, S A; Halloran, P M; Ferris, C A; Levine, B A; Bourret, L A; Goldmacher, V S; Blättler, W A

Shah, S A; Halloran, P M; Ferris, C A; Levine, B A; Bourret, L A; Goldmacher, V S; Blättler, W A.

Affiliation

Shah SA; ImmunoGen, Inc., Cambridge, Massachusetts 02139-4239.

Cancer Res ; 53(6): 1360-7, 1993 Mar 15.

Article in En | MEDLINE | ID: mdl-7680284

Subject(s)

Antigens, CD/immunology; Antigens, Differentiation, B-Lymphocyte/immunology; Immunotoxins/therapeutic use; Leukemia, Experimental/therapy; Lymphoma, B-Cell/therapy; Animals; Antibodies, Monoclonal/therapeutic use; Antigens, CD19; Cell Survival; Female; Humans; Leukemia, Experimental/mortality; Lymphoma, B-Cell/mortality; Mice; Mice, SCID; Neoplasm Transplantation; Phagocytosis; Ricin/therapeutic use; Tumor Cells, Cultured

Search on Google

Add to My VHL

XML

PubMed Links

Database: MEDLINE Main subject: Leukemia, Experimental / Antigens, Differentiation, B-Lymphocyte / Antigens, CD / Immunotoxins / Lymphoma, B-Cell Limits: Animals / Female / Humans Language: En Journal: Cancer Res Year: 1993 Type: Article

Search on Google

Add to My VHL

XML

PubMed Links